Peptide merchant accounts UK
UK peptide sellers need a specialist high-risk acquirer because mainstream processors decline the category outright. Stripe, PayPal, SumUp, Square, Zettle, Worldpay and Barclaycard classify research peptides alongside unlicensed medicines and research chemicals, and either reject at onboarding or terminate and hold funds once the catalogue is reviewed. Specialist research-chemical and nutraceutical acquirers underwrite peptides instead, on a case-by-case basis, at higher blended rates with a substantial rolling reserve against chargebacks and regulatory risk. Expect strict scrutiny of your labelling, disclaimers and claims at compliance.
Legal status (UK)
Sold lawfully in the UK only as research chemicals or laboratory reagents, labelled not for human consumption. Marketing peptides for human use, dosing or injection makes them unlicensed medicines and brings them under MHRA enforcement. The legal position turns entirely on how the product is presented.
Best way to take Peptide payments (UK)
Our pick
MerchantHQ: a specialist Peptide quote through our broker partner
Mainstream UK acquirers (SumUp, Square, Zettle, Dojo, Worldpay, Barclaycard) decline Peptide businesses at onboarding or terminate after launch. Our broker partner works with specialist high-risk acquirers that underwrite it, and works to return 2 to 3 matched quotes for your licence, volume and processing history.
Our broker partner pays us a fee for each introduction, so it costs you nothing on top, and we never sell your details on. Your risk classification travels with the enquiry, so specialist providers are approached from the start.
Get matched to a Peptide acquirerHigh-risk merchants are the most exposed to chargebacks, frozen funds and MATCH/TMF listings. Once you are live your provider runs the account; our free guides cover chargebacks, reserves and frozen funds and MATCH/TMF listings.
How Peptide placements work
Peptide routes to specialist regulated-vertical acquirers matched per application rather than a published list. The right underwriter depends on your licence, volume and sub-category, so our broker partner approaches it individually, disclosing your risk classification upfront so the right acquirer is contacted from the start.
Typical pricing
- Rate
- 3.5% to 8.0% blended
- Settlement reserve
- 10% to 20% rolling reserve common
Indicative ranges based on typical UK high-risk acquirer pricing for this category. Your actual rate and reserve are set per merchant at underwriting and will differ.
Watch outs
- Product pages must label peptides as research chemicals not for human consumption; any human-use, dosing or injection guidance reclassifies them as unlicensed medicines under MHRA rules and triggers acquirer termination.
- No medical, therapeutic, performance or anti-ageing claims anywhere on site, in metadata or in ads.
- Mainstream processors (Stripe, PayPal, SumUp) routinely freeze peptide accounts post-onboarding once the category is identified; have a compliant specialist account in place from day one.
- Age-gating, COA / batch documentation and clear returns terms are reviewed at underwriting.
- GLP-1 peptides (semaglutide, tirzepatide) are prescription-only medicines, not research chemicals; selling them without a pharmacy registration is a separate and more serious offence.
- A certificate of analysis or lab test is required for every product, not a sample of the range; peptide catalogues are typically coded MCC 5999.
- Peptides sold in pill or capsule form are widely treated as intended for human consumption and are refused outright by many acquirers under internal policy; keep the catalogue to non-oral formats.
- Most underwriters require a fixed in-vitro disclaimer in every product description: used solely for in vitro experiments, not for use in human clinical trials, human administration, or supply to a third party for human investigational use.
- If semaglutide is listed, expect to provide a letter confirming compliance with the requirements to sell it, or to remove the products before an acquirer will proceed.
Common questions
Why do mainstream acquirers decline Peptide businesses?
Mainstream UK acquirers (SumUp, Square, Zettle, Dojo, Worldpay, Barclaycard) set risk policies for their typical merchant base, and Peptide usually falls outside it on chargeback rate, regulatory exposure or reputational risk. That is a policy fit issue, not a reflection of your business. Specialist high-risk acquirers price for and underwrite this risk directly, which is why they work with Peptide where mainstream providers will not.
Does a high-risk merchant account cost more?
Usually, yes. Expect a higher transaction rate and a settlement reserve (a percentage of takings held back for a rolling period) rather than same-day or next-day settlement. That is the trade-off for a specialist underwriter taking on chargeback and regulatory risk a mainstream acquirer will not price for at all.
How long does approval take for a high-risk merchant account?
Typically longer than a mainstream application, because the underwriter reviews your licensing, processing history and risk controls individually rather than running an automated check. Bringing a clean processing history, current licensing documents and realistic volume projections to the first application materially speeds this up.
Can I switch to a mainstream acquirer once I am established?
Sometimes, once you have a settled processing history and the underlying risk profile has genuinely reduced, but never guaranteed. Some verticals stay classified as high-risk regardless of trading history because the classification is about the category, not just the individual merchant's record.
Is MerchantHQ a lender or the acquirer?
Neither. MerchantHQ is a comparison and introducer service. Your quote enquiry goes to our card-payments broker partner, Merchant Advice Service (peptide businesses go to Fena instead), which works to return 2 to 3 matched quotes from providers that take your kind of business. The broker pays us a fee for each introduction, so there is no cost to you. The acquirer you choose processes your payments.
Related
See the full high-risk merchant guide, how merchant accounts work, compare card terminals, or check card machine costs.
Founder & Managing Director, Muswell Rose, founder and PSC of Best Business Loans Ltd
Adam is the founder and managing director of Muswell Rose and a founder of Best Business Loans Ltd, the company behind MerchantHQ. His career runs through insurance, mortgages, commercial finance and fintech lending, including payments and merchant services. He writes the MerchantHQ library.
Last updated:
Payments review: Derren Powell, payments and fintech specialist, formerly Vice President, Business Development (Merchants) at Mastercard. Independent reviewer; the MerchantHQ editorial team retains control of the final content.